Dravet Syndrome Global Market Report 2025

The dravet syndrome market size has grown strongly in recent years. It will grow from $0.37 billion in 2024 to $0.4 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to factors such as the increasing prevalence of Dravet syndrome, improved diagnosis rates due to better screening methods, greater funding for epilepsy research, regulatory incentives for orphan drugs, and a higher acceptance of cannabis-based treatments.

The dravet syndrome market size is expected to see strong growth in the next few years. It will grow to $0.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as expanding insurance coverage for rare diseases, increasing patient advocacy, greater affordability of genetic testing, stronger government support for rare disease treatments, and a growing number of specialty neurology clinics. Key trends in the forecast period include advancements in gene therapy for seizure control, the rising use of AI for early diagnosis, the development of precision medicine for personalized treatments, innovations in drug delivery systems for epilepsy management, and the expansion of telehealth for remote patient monitoring.

The growing prevalence of neurological disorders is expected to drive the growth of the Dravet syndrome market. Neurological disorders encompass a wide range of conditions that impact the brain, spinal cord, and nervous system, leading to impairments in movement, cognition, sensation, or other bodily functions. These disorders are becoming more common due to factors such as aging populations, lifestyle changes, environmental influences, better diagnostic methods, and the increasing incidence of neuroinfections and autoimmune diseases. Dravet syndrome plays a significant role in advancing research into neurological disorders, offering valuable insights into genetic mutations, brain excitability, and the development of targeted therapies that could benefit a wider range of conditions. For example, in April 2022, the European Brain Council reported that more than 600 neurological diseases and nearly 300 psychiatric conditions affect millions of people worldwide, with epilepsy alone impacting 65 million individuals. In Europe, 10.5 million people suffer from dementia, with projections suggesting this number will rise to 18.7 million by 2050. Consequently, the growing prevalence of neurological disorders is helping to propel the Dravet syndrome market forward.

Companies involved in the Dravet syndrome market are increasingly focusing on advancements in precision medicine, such as RNA-based therapies, to create targeted treatments that address the genetic mutations underlying Dravet syndrome, aiming to improve treatment effectiveness and minimize side effects. RNA-based therapies involve the use of RNA molecules to modify gene expression or protein production, offering a way to treat genetic disorders by directly targeting the root causes at the molecular level. For example, in December 2024, Stoke Therapeutics Inc., a U.S.-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for zorevunersen, a treatment for Dravet syndrome. This therapy is designed to increase the expression of the SCN1A gene, which is commonly mutated in Dravet syndrome patients, directly addressing the genetic deficiency rather than simply managing the symptoms. By using RNA-based precision medicine, the therapy aims to restore proper neuronal function, potentially reducing the frequency of seizures and improving cognitive outcomes.

In March 2022, Union Chimique Belge (UCB), a Belgium-based pharmaceutical company, acquired Zogenix Inc. for $1.9 billion. This acquisition was intended to strengthen UCB’s presence in the Dravet syndrome market by integrating Zogenix’s expertise and its product FINTEPLA (fenfluramine) oral solution into UCB's neurology portfolio. The deal aims to increase global access to treatments for patients with severe epilepsy and explore additional indications to further solidify UCB’s position in the field of rare neurological disorders. Zogenix Inc. is a U.S.-based company focused on developing therapies for rare diseases, including Dravet syndrome.

Major players in the dravet syndrome market are Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, H. Lundbeck A/S, BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Zogenix Inc., Biocodex S.A., Encoded Therapeutics Inc., Marinus Pharmaceuticals Inc., Arvelle Therapeutics GmbH, Stoke Therapeutics Inc., Longboard Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., GW Pharmaceuticals plc, and Ovid Therapeutics Inc.

North America was the largest region in the dravet syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dravet syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dravet syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dravet syndrome is a rare and severe form of epilepsy that begins in infancy, marked by frequent and prolonged seizures that are often resistant to treatment. It is commonly studied for its genetic link to mutations in the SCN1A gene and for developing targeted therapies aimed at managing seizure activity and improving patient outcomes.

The primary treatment options for Dravet syndrome include seizure medications, the ketogenic diet, vagus nerve stimulation, and other interventions. Seizure medications help prevent or reduce the frequency and intensity of seizures in conditions such as epilepsy and other neurological disorders. In addition to these treatments, diagnostic tests such as magnetic resonance imaging (MRI), electroencephalography (EEG), and sodium voltage-gated channel alpha subunit 1 testing are used. These treatments can be administered through various routes, including parenteral and oral options. The key end users include pharmaceutical companies, hospitals, diagnostic laboratories, and academic and research institutes.

The dravet syndrome market research report is one of a series of new reports that provides dravet syndrome market statistics, including the dravet syndrome industry global market size, regional shares, competitors with the dravet syndrome market share, detailed dravet syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the dravet syndrome industry. This dravet syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dravet syndrome market consists of revenues earned by entities that provide services such as advanced genetic screening, medical consultation and diagnosis, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The dravet syndrome market also includes sales of genetic testing kits, anticonvulsant medications, and emerging gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.